About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

Active Not RecruitingPhase 1NCT04155749

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.

Lead sponsor: Kite, A Gilead Company•4 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Kite, A Gilead Company

Collaborators

Arcellx, Inc.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Relapsed and refractory Multiple Myeloma treated with at least 3 prior regimens of system therapy including Proteosome Inhibitor (PI), immunomodulatory drugs (IMiD), and anti-CD38 antibody (CD38mab); or has "triple-refractory" disease
•Documented measurable disease
•Adequate organ function
•Life expectancy \> 12 weeks, Eastern Cooperative Group Performance Status 0-1

Exclusion Criteria

•Plasma Cell Leukemia or History of Plasma Cell Leukemia
•Patients with a history of severe hypersensitivity to DMSO should be excluded
•Contraindication to fludarabine or cyclophosphamide
•Severe uncontrolled intercurrent illness (e.g., infection) or laboratory abnormalities
•Active central nervous system disease involvement by malignancy or active CNS pathology

Related studies

Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

NCT05673967 · Relapsed and Refractory Multiple Myeloma (RRMM)

TERMINATEDPhase 2

IPD in RRMM Characterized with Genomic Abnormalities of Adverse Prognostic

NCT03683277 · Multiple Myeloma, Relapsed and Refractory Multiple Myeloma, and more

TERMINATEDPhase 1

A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma

NCT03710915 · Multiple Myeloma, Relapsed and Refractory Multiple Myeloma

Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)

NCT03477643 · Relapsed and Refractory Multiple Myeloma

TERMINATEDPhase 1

A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies

NCT02223598 · Lymphoid Hematological Malignancies, Relapsed and Refractory Multiple Myeloma

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 11, 2026Terms

Trial snapshot

StatusACTIVE_NOT_RECRUITING

PhasePHASE1

Enrollment40

Start dateDec 2019

Last updatedFeb 11, 2026

Condition

Relapsed and Refractory Multiple Myeloma

Locations shown

Advanced Cellular Therapeutics Facility, DCAM 0800A

Chicago, Illinois

Massachusetts General Hospital

Boston, Massachusetts

Beth Israel Deaconess Medical Center

Boston, Massachusetts

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 11, 2026Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions